PF-AtlasClinical Trials › NCT04652518

LYT-100 in Post-acute COVID-19 Respiratory Disease

LYT-100 · Phase 2

Registry ID
NCT04652518
Phase
Phase 2
Status
Terminated
Drug / intervention
LYT-100
Sponsor
PureTech
Start
2020-12-11
Enrollment
185
Locations
31

About this trial

This study is being conducted in two parts, A and B. Part A is a randomized, double-blind, parallel arm study to evaluate the safety and efficacy of LYT-100 compared to placebo in adults with post-acute COVID-19 respiratory complications. Part B is an Open Label Extension (OLE) study for patients who complete Part A.

View NCT04652518 on ClinicalTrials.gov →

Explore related

Medical disclaimer. This page summarizes public trial data for NCT04652518 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.